Discovery of New Anti-cancer Molecules: From Hit Identification to Structure-Activity Relationship Study
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 3732
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is the leading cause of mortality worldwide. It is estimated that nearly 10 million deaths were resulted from cancer worldwide in 2021 according to the WHO. The deadliest cancer types include breast, lung, colon and rectum, and skin cancer. Despite the rise of immunotherapy and monoclonal antibodies, natural products from plants, marine organisms, and microorganisms and their synthetic derivatives/analogs are historically employed for cancer treatment and have gained enormous success. Nevertheless, cancer cells can develop multiple mechanisms that include but are not limited to increased drug efflux, drug compartmentalization, target mutation, and gene amplification, eventually leading to reduced effectiveness of chemotherapeutic agents. Therefore, development of anticancer agents that can circumvent drug resistance or discovery of new generation of anticancer agents with novel scaffolds is urgently needed.
This Special Issue will focus on small, molecule-based drug discovery for cancer treatment. We welcome original research articles from 1) a structure-activity relationship study of identified hit, 2) hit identification from high-throughput screening or in silico screening, 3) synergistic combination for cancer treatment, and 4) the isolation of novel bioactive molecules from natural sources. We also welcome comprehensive reviews for specific target proteins.
Dr. Qinghui Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-cancer drug discovery
- SAR
- natural products
- high-throughput screening
- synergistic combination
